Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

<p>Single-gene expression changes of genes in common between baseline and surgery in the different cohorts. <b>A,</b> Scatterplot of differentially expressed genes between baseline and surgery measured by log<sub>2</sub> FC among the entire short-term and long-term AI c...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Milana A. Bergamino (15038015) (author)
Rannpháirtithe:	Gabriele Morani (15038018) (author), Joel Parker (15038021) (author), Eugene F. Schuster (9726535) (author), Mariana F. Leal (15038024) (author), Elena López-Knowles (15038027) (author), Holly Tovey (9360536) (author), Judith M. Bliss (8827107) (author), John F.R. Robertson (15025368) (author), Ian E. Smith (1545553) (author), Mitch Dowsett (645) (author), Maggie C.U. Cheang (14946768) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Tumor Biology Cancer Detection and Diagnosis Therapeutic Research and Development Biomarkers Genetic biomarkers Breast Cancer Drug Resistance Novel mechanisms Endocrinology Translational Research
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
de réir: Milana A. Bergamino (15038015)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
de réir: Lixuan Wei (14962431)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S10 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S11 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S6 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S7 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S8 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S9 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
de réir: Zheqi Li (14961021)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
de réir: Juliana Navarro-Yepes (17079059)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
de réir: Andrés Elía (15055031)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
de réir: Andrés Elía (15055031)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
de réir: Andrés Elía (15055031)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
de réir: Andrés Elía (15055031)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
de réir: Andrés Elía (15055031)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
de réir: Emil Christensen (15054394)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
de réir: Emil Christensen (15054394)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
de réir: Michael D. Nyquist (16918265)
Foilsithe / Cruthaithe: (2025)

Supplemental Figures 1-4 from Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
de réir: Michael D. Nyquist (16918265)
Foilsithe / Cruthaithe: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
de réir: Jamunarani Veeraraghavan (16461809)
Foilsithe / Cruthaithe: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
de réir: Jamunarani Veeraraghavan (16461809)
Foilsithe / Cruthaithe: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
de réir: Jamunarani Veeraraghavan (16461809)
Foilsithe / Cruthaithe: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
de réir: Jamunarani Veeraraghavan (16461809)
Foilsithe / Cruthaithe: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
de réir: Jamunarani Veeraraghavan (16461809)
Foilsithe / Cruthaithe: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
de réir: Jamunarani Veeraraghavan (16461809)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
de réir: Jamunarani Veeraraghavan (16461809)
Foilsithe / Cruthaithe: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
de réir: Andrew A. Davis (15030032)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
de réir: Nicolas A. Giraldo (15050937)
Foilsithe / Cruthaithe: (2025)

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
de réir: Nicolas A. Giraldo (15050937)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
de réir: Nicolas A. Giraldo (15050937)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
de réir: Nicolas A. Giraldo (15050937)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
de réir: Nicolas A. Giraldo (15050937)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_5pjmcv6lm29jp9ohhs4ioms6ej